Cargando…
Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors
Autores principales: | Tian, Shen, Li, Hao, Li, Renhua, Ran, Liang, Li, Shu, Wu, Juan, Xu, Zhou, Liang, Xinyu, Chen, Yuling, Xiao, Jun, Wei, Jiaying, Ma, Chenyu, Song, Jingyu, She, Ruiling, Wu, Kainan, Kong, Lingquan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771262/ https://www.ncbi.nlm.nih.gov/pubmed/36535013 http://dx.doi.org/10.1097/CM9.0000000000002121 |
Ejemplares similares
-
Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?
por: Wu, Juan, et al.
Publicado: (2019) -
Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine
por: Huang, Jianbo, et al.
Publicado: (2013) -
Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease
por: Ran, Li-Sha, et al.
Publicado: (2022) -
DJ-1 Deficiency Protects Hepatic Steatosis by Enhancing Fatty Acid Oxidation in Mice
por: Xu, Min, et al.
Publicado: (2018) -
Survivors of the Punjab Campaigns
por: Wimberley, C. N. C.
Publicado: (1909)